Beam Therapeutics (BEAM) Total Current Liabilities (2019 - 2026)

Beam Therapeutics (BEAM) has reported Total Current Liabilities for 8 consecutive years, with $74.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities fell 47.32% year-over-year to $74.6 million; the TTM figure through Mar 2026 stood at $74.6 million (down 47.32% YoY), while the FY2025 annual figure was $96.9 million, down 46.76% from the prior year.
• Total Current Liabilities eased to $74.6 million in Q1 2026 per BEAM's latest filing, from $96.9 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $238.9 million in Q3 2022 and bottomed at $74.6 million in Q1 2026.
• Historically, Total Current Liabilities has averaged $184.2 million across 5 years, with a median of $187.2 million in 2024.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 135.58% — and 2026, when it plunged 47.32%.
• Beam Therapeutics' Total Current Liabilities stood at $223.6 million in 2022, then retreated by 8.06% to $205.6 million in 2023, then fell by 11.43% to $182.1 million in 2024, then plunged by 46.76% to $96.9 million in 2025, then fell by 23.08% to $74.6 million in 2026.
• Business Quant data shows BEAM's Total Current Liabilities at $74.6 million in Q1 2026, $96.9 million in Q4 2025, and $182.6 million in Q3 2025.